ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
developing genetically-targeted therapies for cardiovascular diseases,
today announced that it has priced its previously announced public
offering of common stock and warrants at a price of $1.70 for each share
of common stock and a related warrant to purchase 0.25 shares of common
stock, for gross proceeds of $8.7 million, prior to deducting
underwriting discounts and commissions and offering expenses of the
Company. The purchase price represents a 9.6% discount to the closing
price of the Company’s common stock on the Nasdaq Capital Market on
February 3, 2014. The warrants are immediately exercisable, have a term
of 5 years and an exercise price of $2.125 per share. The offering is
expected to close on or about February 7, 2014, subject to the
satisfaction of customary closing conditions.
The Company intends to use the net proceeds of the offering for general
corporate purposes, including working capital and operational purposes.
The Company anticipates that its cash and cash equivalents balance of
approximately $16.8 million at December 31, 2013, along with the
estimated net proceeds from this offering, will be sufficient to fund
its operations, at its projected cost structure, through at least 2015.
However, changing circumstances may cause the Company to consume capital
significantly faster or slower than it currently anticipates. The
Company has based these estimates on assumptions that may prove to be
wrong, and the Company could exhaust its available financial resources
sooner than it currently anticipates.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such jurisdiction.
Dawson James Securities, Inc. is acting as the sole book-running manager
for the offering.
The shares and warrants are being offered under the Company’s effective
shelf registration statement previously filed with the Securities and
Exchange Commission (SEC) and declared effective on April 4, 2011
(Registration No. 333-172686).
A preliminary prospectus supplement and accompanying prospectus relating
to the offering has been filed with the SEC and is available on the
SEC's website located at www.sec.gov.
Copies of the preliminary prospectus supplement and accompanying
prospectus may also be obtained by contacting Dawson James Securities,
Inc., Attention: Prospectus Department, 1 North Federal Highway, 5th
Floor, Boca Raton, FL 33432, e-mail: mmaclaren@dawsonjames.com
or toll free at (866) 928-0928 Before you invest, you should read the
preliminary prospectus supplement and accompanying prospectus and other
documents the Company has filed with the SEC for more complete
information about ARCA biopharma, Inc. You may obtain these documents
for free by visiting the SEC web site at www.sec.gov.
About ARCA biopharma
ARCA biopharma is dedicated to developing genetically-targeted therapies
for cardiovascular diseases. The Company's lead product candidate,
GencaroTM (bucindolol hydrochloride), is an investigational,
pharmacologically unique beta-blocker and mild vasodilator being
developed for atrial fibrillation. ARCA has identified common genetic
variations that it believes predict individual patient response to
Gencaro, giving it the potential to be the first genetically-targeted
atrial fibrillation prevention treatment. ARCA has a collaboration with
Medtronic, Inc. for support of the GENETIC-AF trial. For more
information please visit www.arcabiopharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements" for purposes of
the safe harbor provided by the Private Securities Litigation Reform Act
of 1995. These statements include, but are not limited to, statements
regarding, potential timing for patient enrollment in the GENETIC-AF
trial, the sufficiency of the Company’s capital to support its
operations, the potential for genetic variations to predict individual
patient response to Gencaro, Gencaro’s potential to treat atrial
fibrillation, future treatment options for patients with atrial
fibrillation, the role of AF burden in diagnosis and treatment of atrial
fibrillation and the potential for Gencaro to be the first
genetically-targeted atrial fibrillation prevention treatment. Such
statements are based on management's current expectations and involve
risks and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements as a
result of many factors, including, without limitation, the risks and
uncertainties associated with: the Company's financial resources and
whether they will be sufficient to meet the Company's business
objectives and operational requirements; results of earlier clinical
trials may not be confirmed in future trials, the protection and market
exclusivity provided by the Company’s intellectual property; risks
related to the drug discovery and the regulatory approval process; and,
the impact of competitive products and technological changes. These and
other factors are identified and described in more detail in ARCA’s
filings with the SEC, including without limitation the Company’s annual
report on Form 10-K for the year ended December 31, 2012, and subsequent
filings. The Company disclaims any intent or obligation to update these
forward-looking statements.
Copyright Business Wire 2014